Staging recurrent ovarian cancer with 18FDG PET/CT
Open Access
- 13 December 2012
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 5 (2), 593-597
- https://doi.org/10.3892/ol.2012.1075
Abstract
The aim of the present study was to evaluate the use of 2-deoxy-2-(18F)-fluoro-D-glucose (18FDG) positron emission tomography (PET)/computed tomography (CT) in patients with suspected ovarian cancer recurrence and describe the distribution of metastasis. A total of 45 female patients who underwent PET/CT scan due to raised CA-125 levels, clinical suspicion of ovarian cancer recurrence or alterations detected on ultrasound (US), CT or magnetic resonance imaging (MRI) were included in this retrospective study. PET/CT results were compared with histological findings (n=15) or clinical, laboratory and repeated imaging techniques during subsequent follow-up for at least six months (n=30). CA-125 was elevated in 34 patients, 14 patients had clinical symptoms of disease and 23 presented with alterations on US, CT and MRI. A total of 42 patients were confirmed to have ovarian cancer recurrence, all with abnormal findings on PET/CT. Three patients remained free of disease during clinical follow-up, all with normal PET/CT findings. There were 11 patients with raised CA-125 levels and normal conventional imaging, all with positive PET/CT. Among the 11 patients with normal CA-125 levels, eight presented with positive PET/CT scan. Lymph nodes were the most frequent site of relapse of disease, followed by peritoneal implants. Distant sites of metastasis included the liver, spleen, pleura, lung and bone. PET/CT detected unsuspected lesions in 20/45 patients (44.4%). 18FDG PET/CT was a useful tool for evaluating the extent of ovarian cancer recurrence. In the current series, lymph nodes were the most frequent site of relapse of disease, with supradiaphragmatic lymph node metastasis in a large number of cases.Keywords
This publication has 18 references indexed in Scilit:
- Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?European Journal of Nuclear Medicine and Molecular Imaging, 2010
- CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysisEuropean Journal of Radiology, 2009
- 18F-FDG PET/CT evaluation of patients with ovarian carcinomaNuclear Medicine Communications, 2008
- Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrationsThe Lancet Oncology, 2007
- Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literatureInternational Journal of Gynecologic Cancer, 2007
- The impact of PET/CT in the management of recurrent ovarian cancerGynecologic Oncology, 2006
- Treated Ovarian Cancer: MR Imaging, Laparotomy Reassessment, and Serum CA-125 Values Compared with Clinical Outcome at 1 YearRadiology, 2005
- Epidemiology of ovarian cancer: a status reportThe Lancet, 2005
- Cancer of the OvaryNew England Journal of Medicine, 2004
- Ovarian cancer: the clinical role of US, CT, and MRIEuropean Radiology, 2003